Elena Kagan supports human cloning
EXCERPT:
Kagan Files From Clinton Administration Show Her Backing Human Cloning

by Steven Ertelt
LifeNews.com Editor
June 10, 2010

Washington, DC (LifeNews.com) -- Add human cloning to abortion and assisted suicide as practices pro-life groups oppose but Supreme Court nominee Elena Kagan supports. Files released from the Clinton library about Kagan's time in the Clinton administration show her advocating cloning humans for dubious research.

Kagan served as a top domestic policy advisor for ex-President Bill Clinton from 1997-1999 and she played a key role in shaping and executing his response to new cloning technologies.


A 28 billion dollar market
EXCERPT:
Understanding Advanced Cell’s Position

Market Opportunity: Age related macular degeneration (AMD) represents a “tremendous” market opportunity given the size of the patient population and the lack of treatment alternatives. Diseases of the eye affect more than 30 M people worldwide and represent a $20+B market.


Nuclear Transfer and Cloning
EXCERPT:
Italian doctor says he has cloned three babies
Mar 3 01:37 PM US/Eastern

Italian embryologist Severino Antinori addresses a news conference in Rome ...

Designer Babies LA Style: Clinic Offers Genetic Traits Selection

A controversial Italian doctor known for his work allowing post-menopausal women to have children has claimed in an interview to have cloned three babies who are now living in eastern Europe.

Cloning
EXCERPT:
Senior Executive Officers

--------------------------------------------------------------------------------
William M. Caldwell, IV
Chairman and CEO

Mr. William Caldwell serves as Chairman and Chief Executive Officer of the Company and has a 30-year management career working with emerging technologies and restructuring distressed corporate environments. During his career, he has served in senior executive positions both in marketing and finance. He has worked with Booz Allen and Hamilton; the Flying Tiger Line Inc.; Van Vorst Industries; and Kidder Peabody. He started a firm specializing in corporate financial and strategy planning, which was instrumental in restructuring over $1.0 billion of debt for over twenty companies and partnerships. He was a pioneer in the satellite radio auctions as president of Digital Satellite Broadcasting Corporation; assisted in the financing, and became president and ultimately CEO in the restructuring of CAIS Internet. He has advised corporations, both public and private, in technology, telecommunications, retailing, real estate, hospitality, publishing, and transportation. He received his B.A. degree from the University of Southern California and was a Multinational Enterprise Fellow at the Wharton Graduate School of Finance. He serves as a director of Lee Pharmaceuticals (LPHM.PK) and King Koil Franchising Corp.

Somatic cell nuclear transfer
EXCERPT:
Somatic cell nuclear transfer
From Wikipedia, the free encyclopediaJump to: navigation, search

Somatic cell nuclear transfer can create clones for both reproductive and therapeutic purposes. The diagram depicts the removal of the donor nucleus for schematic purposes; in practice usually the whole donor cell is transferred.In genetics and developmental biology, somatic cell nuclear transfer (SCNT) is a laboratory technique for creating a clonal embryo, using an ovum with a donor nucleus (see process below). It can be used in embryonic stem cell research, or, potentially, in regenerative medicine where it is sometimes referred to as "therapeutic cloning." It can also be used as the first step in the process of reproductive cloning.

MiV Investments Inc.
EXCERPT:
MIV investments in 2008 grew by 31%: CGAP survey
Thursday, October 22, 2009, 18:14
Latest News
Add a comment ShareBy Matthew Fuchs

Microfinance Focus, Oct. 22, 2009: Microfinance Investment Vehicles (MIVs) recorded a 31% growth in their total assets in 2008 amounting to $6.6 billion, according to the CGAP MIV Benchmark Survey released recently. Though the estimates show that MIVs grew a further 16% in annualized figures in the first half of 2009, managers of many MIVs are not expecting more than 29% growth by the end of this year.